The stock of TransCode Therapeutics Inc (RNAZ) has seen a 24.56% increase in the past week, with a 19.84% gain in the past month, and a -71.73% decrease in the past quarter. The volatility ratio for the week is 6.19%, and the volatility levels for the past 30 days are at 9.68% for RNAZ. The simple moving average for the last 20 days is 20.32% for RNAZ stock, with a simple moving average of -81.45% for the last 200 days.
Is It Worth Investing in TransCode Therapeutics Inc (NASDAQ: RNAZ) Right Now?
The 36-month beta value for RNAZ is also noteworthy at 0.45. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RNAZ is 17.23M, and at present, short sellers hold a 1.62% of that float. The average trading volume of RNAZ on September 17, 2024 was 1.17M shares.
RNAZ) stock’s latest price update
The stock price of TransCode Therapeutics Inc (NASDAQ: RNAZ) has surged by 22.70 when compared to previous closing price of 0.26, but the company has seen a 24.56% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-17 that Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to TransCode’s proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers Phase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138 BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138.
RNAZ Trading at -19.83% from the 50-Day Moving Average
After a stumble in the market that brought RNAZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.75% of loss for the given period.
Volatility was left at 9.68%, however, over the last 30 days, the volatility rate increased by 6.19%, as shares surge +8.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.69% lower at present.
During the last 5 trading sessions, RNAZ rose by +13.84%, which changed the moving average for the period of 200-days by -97.07% in comparison to the 20-day moving average, which settled at $0.2667. In addition, TransCode Therapeutics Inc saw -95.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNAZ starting from Fitzgerald Thomas A, who purchase 49,350 shares at the price of $0.51 back on Sep 28 ’23. After this action, Fitzgerald Thomas A now owns 56,318 shares of TransCode Therapeutics Inc, valued at $25,168 using the latest closing price.
Dudley Robert Michael, the Chief Executive Officer of TransCode Therapeutics Inc, purchase 98,000 shares at $0.51 during a trade that took place back on Sep 28 ’23, which means that Dudley Robert Michael is holding 180,262 shares at $49,980 based on the most recent closing price.
Stock Fundamentals for RNAZ
Current profitability levels for the company are sitting at:
- -23.67 for the present operating margin
- 0.25 for the gross margin
The net margin for TransCode Therapeutics Inc stands at -23.77. The total capital return value is set at -13.48. Equity return is now at value -1048.70, with -334.48 for asset returns.
Based on TransCode Therapeutics Inc (RNAZ), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -67.97. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -351.8.
Currently, EBITDA for the company is -18.9 million with net debt to EBITDA at 0.18. When we switch over and look at the enterprise to sales, we see a ratio of 2.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In summary, TransCode Therapeutics Inc (RNAZ) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
